Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
This protein carries a human IgG1 Fc tag at the C-terminus
The protein has a calculated MW of 65.0 kDa. The protein migrates as 80-100 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
>95% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
Lyophilized from 0.22 μm filtered solution in 50 mM Tris, 100 mM Glycine, 25 mM Arginine, 150 mM NaCl, pH7.5 with trehalose as protectant.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
Human FGF R4, Fc Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.
The purity of Human FGF R4, Fc Tag (Cat. No. FG4-H5253) is more than 90% and the molecular weight of this protein is around 145-175 kDa verified by SEC-MALS.
Human FGF R4, Fc Tag (Cat. No. FG4-H5253) immobilized on CM5 Chip can bind Human FGF-4 Protein, His Tag (Cat. No. FG4-H51H3) with an affinity constant of 1.48 μM as determined in a SPR assay (Biacore 8K) (QC tested).
Explore our catalog of therapeutic antibody solutions to find the right products for you! We are dedicated to delivering solutions designed to help you drive innovation and push the boundaries of what therapeutic antibodies can be.
We offer a wide range of cell and gene therapy solutions starting from discovery to the clinic. Explore our wide range of proteins, antibodies, kits, and other assays to accelerate the development of your cell and gene therapy.
Organoid Toolbox is a collection of organoid solutions including ready-to-use organoids, organoid differentiation kits, and a variety of services to accelerate the progress of your drug development project.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
Comprehensive cytokine targets including interleukins, growth factors, chemokines, TNFs, etc. are expressed by HEK293 to ensure their natural structure. Their high purity is verified by SDS-PAGE/HPLC/SEC-MALS and high bioactivity is verified by ELISA/SPR/BLI.
Aneuro provides comprehensive tools for neuroscience research, including neuroscience proteins, pre-formed fibrils (PFFs), neural antibodies, neural factors, and more—aiming to accelerate disease modeling, drug screening, and neural mechanism studies.
English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Lenvatinib Mesylate | MK-7902; ER-203492-00; E-7080 | Approved | Eisai Co Ltd | Kisplyx, Lenvima, Lenvima/Kisplyx, 乐卫玛 | United States | Thyroid Neoplasms | Eisai Inc | 2015-02-13 | Neuroendocrine Tumors; Paraganglioma; Thyroid Cancer, Papillary; Melanoma; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Glioma; Lymphoma; Endometrial Neoplasms; Thyroid Neoplasms; Hepatic Insufficiency; Breast Neoplasms; Cholangiocarcinoma; Osteosarcoma; Solid tumours; Carcinoma, Adenoid Cystic; Adenocarcinoma, Follicular; Liver Diseases; Thyroid Carcinoma, Anaplastic; Adenocarcinoma of Lung; Neoplasms; Renal Insufficiency; Pheochromocytoma; Esophageal Neoplasms; Carcinoma, Renal Cell; Ovarian Neoplasms; Liver Neoplasms; Biliary Tract Neoplasms | Details |
Futibatinib | TAS-120 | Approved | Taiho Pharmaceutical Co Ltd, Otsuka Pharmaceutical Co Ltd | LYTGOBI | United States | Cholangiocarcinoma | Taiho Oncology Inc | 2022-09-30 | Central Nervous System Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Endometrial Neoplasms; Lymphoma; Metastatic breast cancer; Sarcoma; Cholangiocarcinoma; Breast Neoplasms; Biliary Tract Neoplasms; Carcinoma, Transitional Cell; Neoplasms; Esophageal Neoplasms; Carcinoma; Stomach Neoplasms; Bone Marrow Neoplasms; Solid tumours | Details |
Erdafitinib | 890E37NHMV; G-024; JNJ-493; JNJ-42756493; TAR-210 | Approved | Astex Pharmaceuticals Inc | Balversa, 博珂 | United States | Carcinoma, Transitional Cell | Janssen Biotech Inc | 2019-04-12 | Carcinoma, Squamous Cell; Osteosarcoma; Sarcoma, Ewing; Neuroblastoma; Prostatic Neoplasms; Bile Duct Neoplasms; Urologic Neoplasms; Histiocytic Sarcoma; Hepatic Insufficiency; Lymphoma; Lymphoma, Non-Hodgkin; Sarcoma; Glioma; Metastatic breast cancer; Carcinoma, Neuroendocrine; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Neoplasms, Germ Cell and Embryonal; Neuroectodermal Tumors, Primitive, Peripheral; Xanthogranuloma, Juvenile; Adenocarcinoma; Hepatoblastoma; Ependymoma; Medulloblastoma; Rhabdomyosarcoma; Hematologic Neoplasms; Bone metastases; Esophageal Neoplasms; Stomach Neoplasms; Carcinoma; Rhabdoid Tumor; Solid tumours; Glioblastoma; Carcinoma, Transitional Cell; Neoplasms; Wilms Tumor; Multiple Myeloma; Urinary Bladder Neoplasms; Central Nervous System Neoplasms; Prostatic Neoplasms, Castration-Resistant; Histiocytosis, Langerhans-Cell | Details |
English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Rogaratinib | BAY-1163877 | Phase 3 Clinical | Bayer AG | Solid tumours; Neoplasms; Carcinoma, Transitional Cell; Urinary Bladder Neoplasms; Breast Neoplasms; Sarcoma; Gastrointestinal Stromal Tumors; Metastatic breast cancer; Carcinoma, Non-Small-Cell Lung | Details |
SC-0011 | SC-0011 | Phase 3 Clinical | Shijiazhuang Zhikang Hongren New Drug Development Co Ltd | Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
AUR-109 | ODM-203; AUR-109 | Phase 2 Clinical | Orion Corp | Ovarian Neoplasms; Liver Neoplasms; Kidney Neoplasms; Solid tumours; Carcinoma, Renal Cell; Urinary Bladder Neoplasms; Pulmonary Fibrosis; Breast Neoplasms; Colorectal Neoplasms; Lung Neoplasms | Details |
Fisogatinib | BLU-554; CS-3008 | Phase 2 Clinical | Blueprint Medicines Corp | Carcinoma, Hepatocellular | Details |
Gunagratinib | ICP-192 | Phase 2 Clinical | Beijing Tiancheng Pharmaceutical Technology Co Ltd | Solid tumours; Biliary Tract Neoplasms; Head and Neck Neoplasms; Stomach Neoplasms; Carcinoma, Transitional Cell; Urinary Bladder Neoplasms; Cholangiocarcinoma; Lung Neoplasms | Details |
Irpagratinib | ABSK-011 | Phase 2 Clinical | ABbisko Therapeutics Co Ltd | Solid tumours; Liver Neoplasms; Carcinoma, Hepatocellular | Details |
BPI-43487 | BPI-43487 | Phase 1 Clinical | Betta Pharmaceuticals Co Ltd | Solid tumours; Biliary Tract Neoplasms; Carcinoma, Hepatocellular | Details |
HS-236 | HS-236 | Phase 1 Clinical | Zhejiang Hisun Pharmaceutical Co Ltd | Solid tumours | Details |
HS-10340 | HS-10340 | Phase 1 Clinical | Changzhou Hengbang Pharmaceutical Co Ltd, Shanghai Hansoh Biomedical Co Ltd, Jiangsu Hansoh Pharmaceutical Group Co Ltd | Solid tumours | Details |
ICP-105 | ICP-105 | Phase 1 Clinical | Nanjing Tianyin Jianhua Pharmaceutical Technology Co Ltd, Beijing Tiancheng Pharmaceutical Technology Co Ltd, Beijing Innocare Pharma Tech Co Ltd | Liver Neoplasms; Solid tumours | Details |
ZSP-1241 | ZSP-1241 | Phase 1 Clinical | Guangdong Zhongsheng Pharmaceutical Co Ltd, Wuxi Apptec Co Ltd | Liver Neoplasms; Biliary Tract Neoplasms; Stomach Neoplasms; Carcinoma; Esophageal Neoplasms; Cholangiocarcinoma; Colorectal Neoplasms; Carcinoma, Hepatocellular | Details |
H3B-6527 | H3B-6527 | Phase 1 Clinical | H3 Biomedicine Inc | Liver Neoplasms; Carcinoma, Hepatocellular | Details |
SYHX-2005 | SYHX-2005; SYHX2005 | Phase 1 Clinical | Cspc Ouyi Pharmaceutical Co Ltd | Solid tumours | Details |
JAB-6343 | Phase 1 Clinical | Jacobio Pharmaceuticals Co Ltd | Solid tumours | Details | |
SY-4798 | SY-4798 | Phase 1 Clinical | Shouyao Holding (Beijing) Co Ltd | Solid tumours; Carcinoma, Hepatocellular | Details |
ABSK-012 | ABSK-012; ABSK012 | Phase 1 Clinical | ABbisko Therapeutics Co Ltd | Solid tumours | Details |
LY-2874455 | LY-2874455 | Phase 1 Clinical | Eli Lilly And Company | Neoplasms; Leukemia, Myeloid, Acute | Details |
This web search service is supported by Google Inc.